La Jolla Pharmaceutical Co. (NASDAQ:LJPC) shares were up 1.8% during trading on Tuesday . The company traded as high as $18.25 and last traded at $17.89, with a volume of 116,974 shares. The stock had previously closed at $17.57.

A number of research analysts have commented on LJPC shares. SunTrust Banks Inc. started coverage on La Jolla Pharmaceutical in a report on Wednesday, June 22nd. They set a “buy” rating and a $30.00 target price on the stock. Jefferies Group reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a report on Wednesday, June 8th. Lake Street Capital started coverage on La Jolla Pharmaceutical in a report on Tuesday, May 24th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Zacks Investment Research raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $39.50.

The company’s market cap is $326.56 million. The stock has a 50 day moving average of $16.70 and a 200 day moving average of $17.53.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.22. On average, analysts forecast that La Jolla Pharmaceutical Co. will post ($3.99) earnings per share for the current year.

A hedge fund recently raised its stake in La Jolla Pharmaceutical stock. P.A.W. Capital Corp boosted its stake in shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical comprises approximately 1.5% of P.A.W. Capital Corp’s holdings, making the stock its 28th largest position. P.A.W. Capital Corp owned about 0.28% of La Jolla Pharmaceutical worth $1,361,000 at the end of the most recent quarter.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.